Weekly Analysts’ Ratings Updates for BlossomHill Therapeutics (BLSM)

Several brokerages have updated their recommendations and price targets on shares of BlossomHill Therapeutics (NASDAQ: BLSM) in the last few weeks:

• 10/3/2026 – BlossomHill Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/30/2026 – BlossomHill Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 9/21/2026 – BlossomHill Therapeutics had its price target raised by Guggenheim from $30.00 to $40.00. They now have a “buy” rating on the stock.
• 9/21/2026 – BlossomHill Therapeutics had its price target raised by Leerink Partners from $36.00 to $40.00. They now have an “outperform” rating on the stock.
• 9/2/2026 – BlossomHill Therapeutics was upgraded by Zacks Research to “hold”.
• 9/1/2026 – BlossomHill Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $36.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $30.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $35.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by Leerink Partners. They set an “outperform” rating and a $36.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by HC Wainwright. They set a “buy” rating and a $35.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by Guggenheim. They set a “buy” rating and a $30.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by Lifesci Capital. They set an “outperform” rating and a $32.00 price target on the stock.
• 9/1/2026 – BlossomHill Therapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $28.00 price target on the stock.
• 8/15/2026 – BlossomHill Therapeutics was upgraded by Wall Street Zen to “hold”.

Insider Activity

In related news, General Counsel Vincent Liptak purchased 2,500 shares of the business’s stock in a transaction on Friday, August 7th. The shares were acquired at an average price of $15.80 per share, for a total transaction of $39,500.00. Following the purchase, the general counsel owned 109,212 shares of the company’s stock, valued at $1,725,549.60. This trade represents a 2.34% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John P. Schmid bought 6,000 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were purchased at an average cost of $16.00 per share, with a total value of $96,000.00. Following the completion of the acquisition, the director owned 6,000 shares in the company, valued at approximately $96,000. This represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 1,573,900 shares of company stock worth $25,181,900 over the last quarter.

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.